Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 23479468.
- Also identified by DOI 10.1212/01.wnl.0000428359.07207.f6.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Based on fair quality Level 3 evidence, Lu et al.(1) note that glatiramer acetate (GA) exposure was not associated with lower mean birthweight, lower mean gestational age, preterm birth (37 weeks), congenital anomaly, or spontaneous abortion. However, GA was given an indeterminate recommendation because further research is needed. The results are not compelling: 3 of the 4 existing human studies of GA were small case series.(1.)
Medical subject headings
- Multiple Sclerosis
- Peptides
- Pregnancy Complications